Fatigue in Survivors of Autoimmune Encephalitis
- PMID: 34389660
- PMCID: PMC8369511
- DOI: 10.1212/NXI.0000000000001064
Fatigue in Survivors of Autoimmune Encephalitis
Abstract
Background and objectives: To evaluate the impact of fatigue after autoimmune encephalitis, determine associations with patients' characteristics, and identify factors that contribute to its development.
Methods: In a first cohort recruited via several encephalitis support organizations, self-reported questionnaires were used to evaluate fatigue, depression, and sleep quality in adults after autoimmune encephalitis. In a second cohort where more in-depth clinical characterization could be performed, adults with encephalitis from 2 tertiary hospitals were evaluated using the same questionnaires. Patients' characteristics were retrospectively captured.
Results: In the first cohort (mean [SD] age; 43 [16] years, 220 [65%] female), 220 of 338 participants (65%) reported fatigue, 175 of 307 (57%) depression, and 211 of 285 (74%) poor sleep quality. In the second cohort (48 [19] years; 43 [50%] women), 42 of 69 participants (61%) reported fatigue, whereas 23 of 68 (34%) reported depression and 44 of 66 (67%) poor sleep quality, despite more than 80% having "good" modified Rankin scale (mRS) scores (0-2). Individuals with anti-NMDA receptor encephalitis reported lower fatigue scores than those with other autoimmune encephalitis types. In a multivariate analysis examining factors at discharge that might predict fatigue scores, only anti-NMDA receptor encephalitis was a (negative) predictor of fatigue and remained so when potential confounders were included.
Discussion: The impact of fatigue after autoimmune encephalitis is prominent and not fully accounted for by depression or sleep quality, nor adequately captured by mRS scores for disability. Fatigue is pervasive across autoimmune encephalitis, although lower scores are reported in anti-NMDA receptor encephalitis. Fatigue should be screened routinely, considered as an outcome measure in clinical trials, and further studied from a mechanistic standpoint.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures


Similar articles
-
Sleep disorders in autoimmune encephalitis.Lancet Neurol. 2020 Dec;19(12):1010-1022. doi: 10.1016/S1474-4422(20)30341-0. Lancet Neurol. 2020. PMID: 33212053 Review.
-
Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.Neurology. 2024 Feb 27;102(4):e208019. doi: 10.1212/WNL.0000000000208019. Epub 2024 Jan 24. Neurology. 2024. PMID: 38266213
-
Sleep Characteristics in Pediatric Anti-N-methyl-d-aspartate (NMDA) Receptor Encephalitis: A Retrospective Cohort Study.J Child Neurol. 2023 Apr;38(5):298-306. doi: 10.1177/08830738231173603. Epub 2023 May 18. J Child Neurol. 2023. PMID: 37203168 Free PMC article.
-
Patient-Reported Outcome Measures in NMDA Receptor Encephalitis.Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200343. doi: 10.1212/NXI.0000000000200343. Epub 2024 Dec 12. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39671210 Free PMC article.
-
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.Mult Scler Relat Disord. 2018 Feb;20:144-152. doi: 10.1016/j.msard.2018.01.007. Epub 2018 Jan 31. Mult Scler Relat Disord. 2018. PMID: 29414288 Review.
Cited by
-
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).Front Neurol. 2024 Aug 13;15:1437913. doi: 10.3389/fneur.2024.1437913. eCollection 2024. Front Neurol. 2024. PMID: 39193150 Free PMC article.
-
Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis.Neurology. 2024 Dec 24;103(12):e210109. doi: 10.1212/WNL.0000000000210109. Epub 2024 Nov 20. Neurology. 2024. PMID: 39566012 Free PMC article.
-
Clinical Outcome Assessments in Encephalitis: A Systematic Review.Neurol Neuroimmunol Neuroinflamm. 2024 Jan;11(1):e200168. doi: 10.1212/NXI.0000000000200168. Epub 2023 Dec 7. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38086078 Free PMC article.
-
Mindfulness-based stress reduction as perceived by individuals with pathological mental fatigue after an acquired brain injury.Sci Rep. 2025 Feb 24;15(1):6680. doi: 10.1038/s41598-025-90452-y. Sci Rep. 2025. PMID: 39994249 Free PMC article.
-
Fatigue and cognitive impairment after COVID-19: A prospective multicentre study.EClinicalMedicine. 2022 Sep 17;53:101651. doi: 10.1016/j.eclinm.2022.101651. eCollection 2022 Nov. EClinicalMedicine. 2022. PMID: 36133318 Free PMC article.
References
-
- Granerod J, Davies NWS, Ramanuj PP, Easton A, Brown DWG, Thomas SL. Increased rates of sequelae post-encephalitis in individuals attending primary care practices in the United Kingdom: a population-based retrospective cohort study. J Neurol. 2017;264(2):407-415. 10.1007/s00415-016-8316-8. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical